Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 80-86

  Nicolini, Franck E ^a,k   Hayette, Sandrine ^b,k   Legros, Laurence ^c,d,k   Rousselot, Philippe ^e,k   Maloisel, Frédéric ^f,k   Tulliez, Michel ^g,k   Guerci, Agnès ^h,k   Charbonnier, Aude ^i,k   Prébet, Thomas ⁱ   Rigal Huguet, Françoise ^a   Chabane, Kaddour ^b   Magaud, Jean Pierre ^b   Paillet, Carole ^j   Pivot, Christine ^j   Michallet, Mauricette ^a,k  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f Clinique Sainte Anne   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j CHU PURPAN   (France)

^k French intergroup for CML (Fi LMC group)   (France)

more..

Author keywords

BCR ABL; BCR ABL mutations; CML; Imatinib resistance; Peg Interferon; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; PEGINTERFERON ALPHA2A;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MENTAL DISEASE; METAPHASE; MULTICENTER STUDY; NERVOUS BREAKDOWN; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PIPERAZINES; POLYETHYLENE GLYCOLS; PYRIMIDINES; REMISSION INDUCTION;

EID: 78650178483     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.010     Document Type: Article

References (32)

1. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
2. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
3. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
4. Marin D., Marktel S., Szydlo R., Klein J.P., Bua M., Foot N., et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet 2003, 362:617-619.
5. Kantarjian H.M., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101:473-475.
6. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997, 337:223-229.
7. Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98:3074-3081.
8. Kantarjian H.M., O'Brien S., Cortes J.E., Shan J., Giles F.J., Rios M.B., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
9. ®-A) in patients with treatment-naive chronic-phase chronic myelogenous leukemia. Leuk Lymph 2007, 48:497-505.
10. Michallet M., Maloisel F., Delain M., Hellmann A., Rosas A., Silver R.T., et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004, 18:309-315.
11. Cervantes F., Camós M., Boqué C., Besses C., Alcalá A., Sureda A. Polyethylene glycol interferon-(2b alone or in combination with low-dose AraC in patients newly diagnosed with chronic myeloid leukemia. Haematologica 2004, 89:870-871.
12. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
13. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
14. Hayette S., Michallet M., Baille M.L., Magaud J.P., Nicolini F.E. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk Res 2005, 29:1073-1077.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
16. Ebos J.M., Tran J., Master Z., Dumont D., Melo J.V., Buchdunger E., et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 2002, 1:89-95.
17. Legros L., Bourcier C., Jacquel A., Mahon F.X., Cassuto J.P., Auberger P., et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004, 104:495-501.
18. Barteneva N., Kantarjian H., Somasundaram B., et al. Interferon-alpha augments the apoptotic effect of STI571 in Ph+-blastic crisis cell lines by inducing trail and Fas (CD95/Apo1). Blood 2000, 96:345a.
19. Tipping A.J., Zafirides G., Mahon F.-X., Goldman J.M., Melo J.V. Response of STI571-resistant cell lines to other chemotherapeutic drugs and signal transduction inhibitors. Blood 2000, 96:98a.
20. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999-2007.
21. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000, 96:3195-3199.
22. O'Brien S., Vallance S.E., Craddock C., Holyoake T.L., Goldman JM PEGIntron and STI 571 Evaluation Study (PISCES) in chronic phase chronic myeloid leukemia. Blood 2001, 98:846a. The UK PISCES group.
23. Hochhaus A., Fischer T., Brümmendorf T., et al. Imatinib (Glivec) and pegylated interferon alpha2a (Pegasys) Phase I/II conbination study in chronic phase chronic myelogenous leukemia (CML). Blood 2002, 100:164a.
24. O'Dwyer M., Mauro M.J., Kuyl J.M., Paquette R., Sawyers C.L., Druker B.J. Preliminary evaluation of the combination of Imatinib Mesylate (Gleevec) in combination with low-dose interferon-alpha for the treatment of chronic phase CML. Blood 2001, 98:846a.
25. Perry C.M., Jarvis B. Peginterferon-(-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 2001, 61:2263-2288.
26. O'hare T., Eide C.A., Deininger M. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
27. von Marschall Z., Scholz A., Cramer T., Schäfer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95:437-448.
28. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
29. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
30. Zonder J.A., Pemberton P., Brandt H., Mohamed A.N., Schiffer C.A. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003, 9:2092-2097.
31. Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154-2160.
32. Baccarani M., Martinelli G., Rosti G., Trabacchi E., Testoni N., Bassi S., et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004, 104:4245-4251.